Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jean-Jacques Body

Showing results (61-70 of 133) with videos related to

Pageof 14
Sort By:
Journal of Bone Oncology|January 11, 2019
A real-world study assessing the use of bone-targeted agents and their impact on bone metastases in patients with prostate cancer treated in clinical practice in EuropeJean-Jacques Body, Roger von Moos, Alex Rider, et al.
Clinical Therapeutics|August 15, 2025
Corrigendum to "The Totality of Evidence for SDZ-deno: A Biosimilar to Reference Denosumab" [Clin Ther. 2024;46:916-926]Barbara Vogg, Johann Poetzl, Arnd Schwebig, et al.
Journal of Bone Oncology|June 13, 2018
Bone-targeted agent treatment patterns and the impact of bone metastases on patients with advanced breast cancer in real-world practice in six European countriesRoger von Moos, Jean-Jacques Body, Alex Rider, et al.
Breast Cancer Research and Treatment|June 20, 2008
Association between farnesoid X receptor expression and cell proliferation in estrogen receptor-positive luminal-like breast cancer from postmenopausal patientsFabrice Journe, Virginie Durbecq, Carole Chaboteaux, et al.
Clinical Therapeutics|September 18, 2024
The Totality of Evidence for SDZ-deno: A Biosimilar to Reference DenosumabBarbara Vogg, Johann Poetzl, Arnd Schwebig, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|February 24, 2005
Evidence-based guidelines for the treatment of postmenopausal osteoporosis: a consensus document of the Belgian Bone ClubSteven Boonen, Jean-Jacques Body, Yves Boutsen, et al.
The Journal of Clinical Endocrinology and Metabolism|February 25, 2022
Response to Letter to the Editor From Taguchi: "Osteonecrosis of the Jaw and Antiresorptive Agents in Benign and Malignant Diseases: A Critical Review Organized by the ECTS"Athanasios D Anastasilakis, Jessica Pepe, Nicola Napoli, et al.
Pain|September 15, 2004
Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancerJean-Jacques Body, Ingo J Diel, Richard Bell, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|October 12, 2005
Evidence-based guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis: a consensus document of the Belgian Bone ClubJean-Pierre Devogelaer, Stefan Goemaere, Steven Boonen, et al.
The Journal of Clinical Endocrinology and Metabolism|December 18, 2021
Osteonecrosis of the Jaw and Antiresorptive Agents in Benign and Malignant Diseases: A Critical Review Organized by the ECTSAthanasios D Anastasilakis, Jessica Pepe, Nicola Napoli, et al.
Pageof 14

Showing results (61-70 of 133) with videos related to

Sort By:
Pageof 14
Journal of Bone Oncology|January 11, 2019
A real-world study assessing the use of bone-targeted agents and their impact on bone metastases in patients with prostate cancer treated in clinical practice in EuropeJean-Jacques Body, Roger von Moos, Alex Rider, et al.
Clinical Therapeutics|August 15, 2025
Corrigendum to "The Totality of Evidence for SDZ-deno: A Biosimilar to Reference Denosumab" [Clin Ther. 2024;46:916-926]Barbara Vogg, Johann Poetzl, Arnd Schwebig, et al.
Journal of Bone Oncology|June 13, 2018
Bone-targeted agent treatment patterns and the impact of bone metastases on patients with advanced breast cancer in real-world practice in six European countriesRoger von Moos, Jean-Jacques Body, Alex Rider, et al.
Breast Cancer Research and Treatment|June 20, 2008
Association between farnesoid X receptor expression and cell proliferation in estrogen receptor-positive luminal-like breast cancer from postmenopausal patientsFabrice Journe, Virginie Durbecq, Carole Chaboteaux, et al.
Clinical Therapeutics|September 18, 2024
The Totality of Evidence for SDZ-deno: A Biosimilar to Reference DenosumabBarbara Vogg, Johann Poetzl, Arnd Schwebig, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|February 24, 2005
Evidence-based guidelines for the treatment of postmenopausal osteoporosis: a consensus document of the Belgian Bone ClubSteven Boonen, Jean-Jacques Body, Yves Boutsen, et al.
The Journal of Clinical Endocrinology and Metabolism|February 25, 2022
Response to Letter to the Editor From Taguchi: "Osteonecrosis of the Jaw and Antiresorptive Agents in Benign and Malignant Diseases: A Critical Review Organized by the ECTS"Athanasios D Anastasilakis, Jessica Pepe, Nicola Napoli, et al.
Pain|September 15, 2004
Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancerJean-Jacques Body, Ingo J Diel, Richard Bell, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|October 12, 2005
Evidence-based guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis: a consensus document of the Belgian Bone ClubJean-Pierre Devogelaer, Stefan Goemaere, Steven Boonen, et al.
The Journal of Clinical Endocrinology and Metabolism|December 18, 2021
Osteonecrosis of the Jaw and Antiresorptive Agents in Benign and Malignant Diseases: A Critical Review Organized by the ECTSAthanasios D Anastasilakis, Jessica Pepe, Nicola Napoli, et al.
Pageof 14